n ambitious UK government effort to help underwrite the cost of cancer treatments may have been a worthless bust, according to a new analysis.

Known as the Cancer Drugs Fund, the program was established in 2010 to provide patients with access to cancer drugs not available through the National Health Service because the treatments were not viewed as cost effective by a separate UK government agency. Since then, the fund has spent about $1.5 billion to treat some 100,000 people, although more recently, its finances have been strained.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy